Results 81 to 90 of about 98,309 (302)

Targeting CD20 in chronic lymphocytic leukemia

open access: yes, 2015
Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody ...
Nahas MR, Arnason JE
core  

Long‐Term Follow Up of Two Patients With Variants in the Cluster 1031‐1159 of TRRAP Gene: Expanding the Phenotype of Developmental Delay With or Without Dysmorphic Facies and Autism

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The transformation/transcription domain‐associated protein (TRRAP) gene encodes a large multidomain protein, a member of the phosphatidylinositol 3‐kinase‐related kinase (PIKK) family. TRRAP is a component of the histone acetyltransferase (HAT) complex, and it plays an important role in gene transcription, DNA repair, and cell‐cycle regulation.
Roseli Maria Zechi‐Ceide   +10 more
wiley   +1 more source

Implication de l'association CD20/CD40 dans la mort cellulaire induite via le CD20

open access: yes, 2012
CD20 est une phosphoprotéine transmembranaire exprimée spécifiquement à la surface des lymphocytes B. Malgré les nombreuses études qui ont montré son implication dans le flux calcique, son rôle physiologique est assez mal connu.
Al-Zoobi, Loubna
core   +2 more sources

Porcine kidney xenotransplantation: From primate models to clinical reality

open access: yesAnimal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo   +3 more
wiley   +1 more source

Ofatumumab: a novel monoclonal anti-CD20 antibody

open access: yes, 2010
Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic
Thomas S Lin
core  

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello   +20 more
wiley   +1 more source

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

open access: yesHaematologica, 2009
The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells.
Marieke Griffioen   +5 more
doaj   +1 more source

Kinetic uptake of 99mTc anti-CD20 IgG-SH in CD20+ or CD20- Tumor determined by planar scintigraphy.

open access: yes, 2015
Data are expressed as ratio between tumor and normal tissue background (muscle). Significant differences were observed between CD20+ and CD20- tumor/muscle ratio at 2h30 and 12h (p = 0,03) and at 24 h (p = 0,02).
Isabelle Quelven (803908)   +3 more
core   +1 more source

FMC7 ist Teil des CD20-Antigenkomplexes [PDF]

open access: yes, 2004
Das FMC7-Antigen, eine unbekannte B-Zell-Membranstruktur, dient als eines der immunphänotypischen Grundkriterien zur Diagnose der typischen B-CLL.
Jordanova, Maya
core   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

open access: yesAnnals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy